Why protocol popularity is not the same as profitability
In an IV therapy practice, the most popular drip is often the one everyone talks about first: the Myers-style cocktail, the immune support bag, the NAD+ protocol, the recovery drip, the beauty blend, or the custom hydration package. It shows up in the schedule constantly, drives repeat visits, and becomes the anchor of the menu.
That volume can hide a margin problem. A protocol may sell well because the price feels accessible, the ingredients sound premium, or the visit feels comprehensive. But if the protocol uses costly compounds, takes longer to deliver, includes add-ons that are not priced correctly, or creates more waste than expected, it can generate strong revenue with weak profit.
The operating question is not, "Which drip sells the most?" It is, "Which protocol produces the best margin after the actual ingredients and supplies used in the infusion are attached to the visit?"
The protocol margin formula
A useful protocol margin calculation starts at the completed infusion level. Monthly supply spend is too broad. Menu price is too optimistic. You need the revenue collected for the specific service and the direct cost of what was used to deliver it.
Protocol margin = protocol revenue - ingredient COGS - disposables - expected waste - included visit costs - delivery-model costs
The formula is simple. The discipline is in the inputs. If a practice averages ingredient costs across the month, rounds add-ons into generic categories, or ignores waste and kit movement, the result will look precise without being true.
The cost inputs every IV protocol needs
IV therapy margin depends on more than the bag label. Each protocol should carry the cost of the actual components used during the visit.
- Base fluid and core ingredients. The saline or fluid base, vitamins, minerals, amino acids, antioxidants, medications, and specialty compounds included in the protocol.
- Add-ons and boosters. B12, glutathione, anti-nausea medication, extra vitamin pushes, or custom ingredients that are easy to underprice when they are treated as casual upsells.
- Lot-level unit cost. The actual cost basis of the lot used. If the same compound was purchased at different prices across orders, an average can blur the true margin of the visit.
- Disposables and prep supplies. Tubing, catheters, syringes, flushes, alcohol prep, dressings, labels, and other supplies that look small individually but move the margin line when repeated hundreds of times.
- Waste and expiration risk. Opened vials, partial containers, compounded products, and older lots that expire before they can be used all need a cost record. Waste that is not logged becomes unexplained margin compression.
- Delivery-model cost. Mobile IV services, pop-ups, multi-location stock transfers, and event kits add costs that a single-location chair model may not carry.
Where IV therapy margin usually leaks
Premium ingredients bundled into flat pricing
Flat pricing is easy for patients to understand, but it can become dangerous when customizations are common. A provider may add glutathione, extra B vitamins, magnesium, or anti-nausea medication because the patient expects a more complete experience. If those ingredients are included informally instead of priced and tracked, the protocol margin changes without anyone seeing it.
High-cost protocols with long delivery time
Some protocols use expensive ingredients and require longer chair time or monitoring. NAD+ is the obvious example, but it is not the only one. A premium protocol may need a higher price point, tighter package structure, or a different capacity plan to remain profitable. Revenue alone will not show that.
Expired or stranded stock
IV therapy inventory often includes products with meaningful expiration risk. A clinic may stock ingredients for a protocol that sells inconsistently, then discover that older lots aged out while newer supplies were opened first. Without FEFO rotation and expiration alerts, the protocol looks profitable until the write-off happens.
Mobile kits and location movement
Mobile IV businesses and multi-location practices have another visibility problem: stock leaves the central supply area. It moves to vehicles, provider bags, treatment rooms, events, and pop-up locations. If that movement is not logged, ingredient usage can be disconnected from the service that consumed it.
A simple protocol margin example
Consider an IV practice that sells a recovery drip for $225. The menu price looks healthy. The real margin depends on the components attached to that completed infusion.
| Line item | Cost |
|---|---|
| Base fluid and standard ingredients | $32 |
| Glutathione add-on included in package | $18 |
| Disposables and prep supplies | $11 |
| Expected waste and expiration allocation | $9 |
| Mobile kit and travel allocation | $16 |
| Total direct cost | $86 |
| Gross margin | $139 / 62% |
That might still be a strong protocol. But if the practice thought the direct cost was $43 because it only counted the base ingredients, the pricing decision was being made from half the picture. The risk compounds when the same logic is applied across packages, memberships, and mobile events.
How to compare protocols like an operator
Once ingredient-level COGS is attached to completed visits, the practice can compare protocols by contribution, not just volume.
- Margin dollars per completed infusion. A slower-selling protocol with higher contribution may deserve more promotion than a popular low-margin drip.
- Margin percentage by protocol. This shows whether pricing, bundling, and add-ons are holding up after actual product use.
- Waste rate by ingredient. Identifies the compounds that expire, sit unused, or create write-offs.
- Provider or location variance. Shows whether the same protocol costs more to deliver depending on who prepares it or where it is delivered.
- Package and membership margin. Reveals whether bundled pricing is making high-cost protocols too cheap when patients choose them repeatedly.
What changes when protocol margin is visible
Protocol margin visibility does not mean cutting ingredients or making care feel transactional. It means pricing and packaging services from the economics of the business rather than from a rough sense of what the market will tolerate.
The practice can adjust package rules, separate premium add-ons, retire low-volume ingredients, tighten ordering, enforce FEFO rotation, and decide which protocols deserve marketing support. Those are operating decisions. They require operating data.
The honest summary
IV therapy practices do not lose margin only because of bad pricing. They lose it because the cost of each drip is more specific than the menu usually admits. Ingredient mix, lot cost, waste, add-ons, disposables, and delivery model all matter.
The practices that scale profitably are the ones that know which protocols deserve volume before they push more patients into them. Revenue shows what sold. Protocol margin shows what was worth selling.
Know every drip margin
Otzaro records ingredient-level COGS, supply usage, lot selection, and waste at the infusion level.
The walkthrough shows how protocol profitability, supply inventory, and multi-location visibility work for IV therapy practices.
Frequently asked questions
How do you calculate IV therapy protocol margin?
IV therapy protocol margin is calculated by subtracting ingredient COGS, supplies, waste, labor or included visit costs, and location or mobile delivery costs from the revenue collected for the protocol. The useful version is calculated per completed infusion, not from average monthly supply spend.
Why can a popular IV protocol be less profitable than a slower-selling protocol?
Popularity measures volume, not margin. A high-demand protocol can use expensive ingredients, frequent add-ons, longer chair time, mobile delivery, or more waste. If pricing does not reflect those direct costs, the protocol can produce strong revenue while contributing weak profit.
What costs should an IV therapy practice track for each drip?
Each drip should carry the actual lot-level cost of vitamins, amino acids, minerals, medications, fluids, add-ons, disposables, expected waste, and any delivery-model costs that are directly tied to the infusion, such as mobile kit usage or location-specific stock movement.
Can spreadsheets track IV protocol profitability accurately?
Spreadsheets can model planned IV protocol margins, but they usually break down after real visits happen. True margin depends on the exact ingredients used, lots selected, add-ons administered, waste logged, and supplies consumed at the point of service.
What is the most important profitability metric for an IV therapy practice?
Gross margin per completed protocol is the core operating metric. It shows which drips, boosters, and packages are worth scaling after direct product and supply costs are attached to the actual infusion.